Herceptin Manufacturer Genentech Forcing Consumers to Overpurchase the Cancer Drug Class Action Investigation

Investigating a class action lawsuit on behalf of individuals and agencies using the drug Herceptin.  Genentech, the manufacturer of the cancer drug, appears to have misrepresented the amount of Herceptin contained in a single vial of the reconstituted solution.  Genentech instructs consumers to combine a 440mg vial of Herceptin with 20mL of dissolving liquid.  It then claims the resulting solution will contain 21 mg/mL of the cancer drug, when it will not.    As a result, patients are improperly dosed, and either paying for more Herceptin than intended, or paying full price, but receiving less than what is required.  If you use the drug Herceptin, or are a healthcare provider that treats patients with Herceptin, please contact us for a free consultation.

​

Disclaimer